跳转至内容
Merck
CN
  • Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques.

Global histone H3 lysine 27 triple methylation levels are reduced in vessels with advanced atherosclerotic plaques.

Life sciences (2014-12-03)
Rutger J Wierda, Inge M Rietveld, Marja C J A van Eggermond, Jeroen A M Belien, Erik W van Zwet, Jan H N Lindeman, Peter J van den Elsen
摘要

Alterations in epigenetic processes are frequently noted in human disease. These epigenetic processes involve methylation of DNA and post-translational modifications of histones. It is well established that in particular histone methylation plays a key role in gene transcription. In this study, we have investigated the relationship between triple methylation of lysine 27 in histone H3 (H3K27Me3) modifications and atherosclerotic plaque stage. 28 peri-renal aortic tissue patches covering the entire spectrum of atherosclerotic plaque development were evaluated by immunohistochemistry for the levels of H3K27Me3, EZH2, JMJD3 and BMI1. The results of our studies are in support of a reduction in global levels of the H3K27Me3 modification in vessels with advanced atherosclerotic plaques. This reduction in H3K27Me3 levels is not accompanied by alterations in global levels of the corresponding histone methyltransferase EZH2, the catalytic subunit of the polycomb repressive complex 2 (PRC2). Likewise no alterations in global levels of BMI1, a component of the PRC1 complex, which binds to H3K27Me3-modified histones or the global expression levels of the histone demethylase JMJD3, which removes the methyl marks on H3K27, were observed. Together, our data show that in atherosclerosis development alterations in global levels of H3K27Me3 occur. The reduction in the number of nuclei in the tunica media that display the repressive H3K27Me3 mark in vessels with advanced atherosclerosis plaques therefore could be a reflection of the dynamic pattern of smooth muscle cell differentiation and proliferation associated with atherosclerotic disease.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
甘氨酸, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
纯乙醇, 200 proof, anhydrous, ≥99.5%
Sigma-Aldrich
甘氨酸, suitable for electrophoresis, ≥99%
Sigma-Aldrich
无水柠檬酸粉末, ACS reagent, ≥99.5%
Sigma-Aldrich
纯乙醇, 190 proof, ACS spectrophotometric grade, 95.0%
Sigma-Aldrich
甘氨酸, BioUltra, Molecular Biology, ≥99.0% (NT)
Sigma-Aldrich
甘氨酸, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, ≥98.5%
Sigma-Aldrich
无水柠檬酸粉末, ≥99.5%, FCC, FG
Sigma-Aldrich
无水柠檬酸粉末, 99%
Sigma-Aldrich
无水柠檬酸粉末, anhydrous, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
苏木精
Sigma-Aldrich
纯乙醇, 190 proof, meets USP testing specifications
SAFC
甘氨酸
Sigma-Aldrich
无水柠檬酸粉末, BioUltra, anhydrous, ≥99.5% (T)
Sigma-Aldrich
苏木精, certified by the BSC
Sigma-Aldrich
邻二甲苯, anhydrous, 97%
Sigma-Aldrich
甘氨酸, BioXtra, ≥99% (titration)
Sigma-Aldrich
甘氨酸, ACS reagent, ≥98.5%
Sigma-Aldrich
无水柠檬酸粉末, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%
Supelco
10% (v/v) 乙醇标准品, 10 % (v/v) in H2O, analytical standard
Sigma-Aldrich
2-羟基丁酸 钠盐, 97%
Sigma-Aldrich
甘氨酸, 99%, FCC
Sigma-Aldrich
甘氨酸, meets analytical specification of Ph. Eur., BP, USP, 99-101% (based on anhydrous substance)
Sigma-Aldrich
甘氨酸, puriss. p.a., reag. Ph. Eur., buffer substance, 99.7-101% (calc. to the dried substance)
Sigma-Aldrich
80% v/v 乙醇固定液, suitable for fixing solution (blood films)
Sigma-Aldrich
纯乙醇, 190 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 200 proof, ACS reagent, meets USP testing specifications, Excise Tax-free, Permit for use required
Sigma-Aldrich
纯乙醇, 160 proof, Excise Tax-free, Permit for use required
Sigma-Aldrich
甘氨酸, Vetec, reagent grade, 98%